Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rhenium-188 perrhenate
- Development stage
- Unknown
- Lead developer
- Jiangsu Atom Bioscience & Pharmaceutical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Intra-arterial, Topical
01
Overview
Rhenium-188 perrhenate is a radiopharmaceutical agent consisting of the radioactive isotope rhenium-188 in its perrhenate form. It is a beta-emitting radionuclide with a physical half-life of approximately 16.9-17 hours and a gamma emission at 155 keV, which allows for both therapeutic applications and scintigraphic imaging (theranostics). The agent is typically produced via elution from a tungsten-188/rhenium-188 generator system. Its mechanism of action involves the delivery of localized beta radiation to target tissues, which induces DNA damage, cell cycle arrest, and apoptosis. Clinical investigations have focused on its use for the palliation of metastatic bone pain, the treatment of unresectable hepatocellular carcinoma (often via transarterial radioembolization), and the management of skin keloids.
- Other names
- sodium perrhenate [Re-188]rhenium (188Re) perrhenate188Re-perrhenate
02
Targets
DNA
Beyond the preview
Go deeper on rhenium-188 perrhenate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rhenium-188 perrhenate.